Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies.

ABSTRACT: Cells must maintain their proteome homeostasis by balancing protein synthesis and degradation. This is facilitated by evolutionarily-conserved processes, including the unfolded protein response and the proteasome-based system of protein clearance, autophagy, and chaperone-mediated autophagy. In some hematological malignancies, including acute myeloid leukemia, misfolding or aggregation of the wild-type p53 tumor-suppressor renders cells unable to undergo apoptosis, even with an intact p53 DNA sequence. Moreover, blocking the proteasome pathway triggers lymphoma cell apoptosis. Extensive studies have led to the development of proteasome inhibitors, which have advanced into drugs (such as bortezomib) used in the treatment of certain hematological tumors, including multiple myeloma. New thera

SUBMITTER: Wolska-Washer A 

PROVIDER: S-EPMC9367439 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature